Retrospective evaluation of adverse events of neoadjuvant or induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal squamous cell carcinoma

Esophagus

Volumn 10, Issue 2, 2013, Pages 65-69

  Sugawara, Mitsuhiro ^a   Katada, Chikatoshi ^b   Katada, Natsuya ^b   Takahashi, Kaoru ^a   Higuchi, Katsuhiko ^b   Komori, Shouko ^b   Moriya, Hiromitsu ^b   Ishiyama, Hiromichi ^b   Yamashita, Keishi ^b   Sakuramoto, Shinichi ^b   Tanabe, Satoshi ^b   Koizumi, Wasaburo ^b   Yago, Kazuo ^c  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

DCF; Esophageal cancer; FP; Induction chemotherapy; Neoadjuvant chemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER STAGING; CONSTIPATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DYSGEUSIA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HICCUP; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ORAL MUCOSITIS; PHARYNGEAL MUCOSITIS; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

EID: 84879310763     PISSN: 16129059     EISSN: 16129067     Source Type: Journal    
DOI: 10.1007/s10388-013-0365-9     Document Type: Article

References (17)

1. Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: Japanese Oncology Group Study (JCOG9204). J Clin Oncol. 2003;21:4592-6.
2. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-Term Results of a Randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062-7.
3. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681-92.
4. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68-74.
5. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992;22:172-6.
6. Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell carcinoma of the esophagus. Arch Surg. 1992;127:1446-50.
7. Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg. 1997;114:210-7.
8. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979-84.
9. Ancona E, Roul A, Santi S, Merigliano S, Sileni VC, Koussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improve the long-term survival of patients with resectable squamous cell carcinoma. Cancer. 2001;91:2165-74.
10. van Custem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-7.
11. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695-704.
12. Posner MR, Hershock DM, Blajman CR, Mickiewics E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705-15.
13. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101:498-506.
14. Tanaka Y, Yoshida K, Sanada Y, Osada S, Yamaguchi K, Takahashi T. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer Chemother Pharmacol. 2010;66:1159-65.
15. Yokota T, Hatooka S, Ura T, Abe T, Takahari D, Shitara K, et al. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res. 2011;31:3535-42.
16. Yamasaki M, Miyata H, Tanaka K, Shiraishi O, Motoori M, Peng YF, et al. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology. 2011;80:307-13.
17. Tamura S, Imano M, Takiuchi H, Kobayashi K, Imamoto H, Miki H, et al. Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res. 2012;32:1403-8.